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Classical Hodgkin’s lymphoma (cHL) accounts for 10% of all lymphoma diagnosis. The peculiar feature of the
disease is the presence of large multinucleated Reed-Sternberg (RS) and mononuclear Hodgkin (H) cells interspersed
with a reactive microenvironment (ME) [1]. The latter can represent more than 95% of the entire tumoral mass and
consists of T and B lymphocytes, neutrophils, eosinophils, macrophages, plasma cells, mast cells, fibroblasts and
vessels [1]. The kind and the quantity of these populations in the inflammatory background determine the distinction
of cHL in histological subtypes: nodular sclerosis, mixed cellularity, lymphocyte depleted and lymphocyte rich. RS
and H cells, by secreting numerous cytokines, recruit and set the functional status of the immune infiltrates. The
complex network of paracrine and direct interactions between neoplastic clone and the ME, generates prosurvival
and anti-apoptotic signals in RS and H cells and favors the escape of tumoral cells from immunosurveillance.
After standard chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) and radio-
therapy when indicated, almost all patients with cHL have a remission; however 30% of advanced stages and
15% of early stages have a relapse after treatment [2]. Early relapse defines a drug resistant subgroup associated to
poor prognosis throughout all subsequent treatments. The German Hodgkin Study Group (GHSG) reported a
higher efficacy of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and
prednisone (escalated BEACOPP) compared with ABVD in advanced stage cHL; however because of greater
toxicity and increased risk of second cancers, the long-term survival of the two protocols resulted not significantly
different [3,4]. Therefore accurate prognostication is needed to identify, at time of diagnosis, high-risk patients to be
steered toward more intensified therapy and low-risk patients to be considered for treatment reduction to diminish
long-term toxic effects. A commonly used tool to stratify patients with advanced-stage cHL is the International
Prognostic Score (IPS), a clinical model based on seven clinical parameters associated with a poorer outcome (male
sex, age ≥45 years, stage IV, albumin <40 g/l, white blood cell (WBC) count ≥15 × 109/l, lymphocyte count
<0.6 × 109/l or 8% of differential, hemoglobin <105 g/l) [5]. The IPS defines subgroups of patients with 5-year
freedom from progression ranging from 62 to 88% and with overall survival ranging from 67 to 98% [5]. However,
IPS is not useful in early stages, a significant proportion of patients allocated to the high-risk group achieve durable
complete response with the ABVD scheme and moreover, its utility is limited for risk stratification of patients
treated with escalated BEACOPP regimen, as the latter was effective across all IPS risk groups. Therefore, many
clinicians believe that IPS has a limited clinical value and that is not the best method to select patients who could
benefit from a more aggressive treatment. Numerous studies suggested that the interim functional assessment of
treatment response by fluorodeoxyglucose (FDG)-PET after two ABVD cycles (PET-2) is the strongest predictor
of treatment failure in advanced cHL, proving superior to the IPS [6]. In a retrospective, international, multicenter
study carried out by Gallamini et al., the 3-year progression-free survival (PFS) rate was 28% for patients with PET-2
positive scans and 95% for those with a negative interim PET [7]. The efficacy of intensified treatment strategy
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adapted on PET-2 results in advanced stage cHL were evaluated in several prospective trials where PET-2 positive
patients after two cycles of ABVD were shifted to a escalated BEACOPP regiments while PET-2 negative patients
proceeded with the ABVD scheme [8–10]. The results indicate that response-adapted therapy based on PET-2 results
guarantees a PFS, in PET-2 positive patients and in the overall cohort, higher than PFS of historical controls treated
with ABVD. Furthermore, Johnson P et al. demonstrated that, in advanced cHL, omission of bleomycin from the
ABVD regimen, after a negative PET-2, reduced incidence of pulmonary toxic effects without a significant lowering
of efficacy compared with standard ABVD scheme [11]. However, some warnings limit the use of a PET-2 adapted
treatment in patients with cHL: in early-stage disease, the positive predictive value of PET-2 was low, because of
the low a priori risk of relapse and the high efficacy of radiotherapy in treating patients with this disease and, in
advanced-stage disease, the negative predictive value proved suboptimal, because a variable proportion of patients
(5–12%), despite a negative PET-2 scan, do have treatment failure [8,12]. The limitations of clinical and PET based
models stimulated the development of effective biological prognosticators to be assessed at the time of diagnosis.
Many biomarkers were associated with treatment outcome of cHL. The emerging evidence that the dynamics of
the ME influence the clinical behavior of the disease makes the immune-infiltrates and the network of interactions
they establish with RS and H cells a potential source of new prognosticators. The studies examining the clinical
significance of certain T-cell subsets proved sometimes to be poorly concordant or highlighted survival correlates
apparently conflicting with cancer biology (e.g., prognostically negative impact of cytotoxic T-cells or favorable
outcome of cases with ME enriched in FOXP3+ regulatory T cells) [13]. Gene expression profiling (GEP) recog-
nized a signature of tumor associated macrophages (TAM) being associated with poor prognosis [14]. Steidl C et al.
using immunohistochemistry (IHC), correlated increased number of CD68+ macrophages with a shorter PFS and
with a higher risk of relapse after autologous hematopoietic stem-cell transplantation [14]. The prognostic value of
immunohistochemical quantification of TAM exceeded IPS and was validated in the setting of multicenter Phase
III randomized controlled clinical trial E2496 [15]. Although not all the case series confirmed the prognostic role of
macrophages, several studies suggest that a high number of either CD68+ or CD163+ TAMs is a strong predictor
of adverse outcomes in ABVD treated cHL [16]. However, some further work (e.g., standardization of scoring
methodologies and markers) seems needed to establish if IHC-based assessment of TAM can be used prospectively
to improve prognostic stratification of patients and to plan appropriate therapeutic strategies. Recently, CD68
was indicated to be an important prognostic marker also in a large prospective cohort of patients treated with
upfront escalated BEACOPP in a PET-guided strategy [17]. High CD68 expression at diagnosis was associated to a
higher probability of PET-2 positive scan and the combination of these two data identified a population of patients
with higher risk of treatment failure [17]. This latter finding is in line with a retrospective European multicenter
cohort study that showed a complementary role of interim PET and biomarkers in predicting treatment outcome
in patients with cHL treated with ABVD [18]. In particular was constructed a model combining the PET-2 scan
evaluation with immunohistochemical quantification of CD68+ and PD1+ cells in ME and of STAT1 expression
in RS and H cells. Although no other factor was better than a positive interim PET scan in predicting treatment
failure, the proposed algorithm correctly reclassified the response to treatment in more than half of patients with
treatment failure despite a negative PET-2 scan, thus increasing the negative predictive value of PET-2 [18].
A promising approach is the development of gene expression-based prognostic models with technology platforms
working on the highly fragmented RNA extracted from routinely produced formalin-fixed paraffin-embedded tissue.
Scott et al., using multiplex digital GEP on the NanoString platform, examined genes associated with outcome
or genes representative of ME components that have been previously identified by IHC and GEP [19]. A 23-gene
outcome predictor was then generated that exceeded the IPS and CD68 in identifying patients with advanced-
stage cHL at increased risk of death when treated with ABVD and Stanford V upfront regimens [19]. Recently, a
further prognostic model created by NanoString digital GEP and based on tumor ME biology in relapsed biopsies,
predicted post-autologous hematopoietic stem-cell transplantation outcomes in cHL [20].
Other groups tracked inflammatory markers and signaling proteins reflecting tumor biology, the ME and the
host response in peripheral blood. Kanakry JA et al. showed that, in cHL patients enrolled in the Intergroup
E2496 randomized controlled trial, soluble markers, such as TARC/CCL-17 and soluble CD163 (sCD163), were
related to tumor burden and active disease [21]. Moreover, they found that CXCL-10/IP10 and sCD163 were
associated to inferior FFS and overall survival independent of IPS and treatment [21]. In the study of Romano et al.,
patients showing high serum level of Arginase-1, an immunosuppressive molecule produced by neutrophils and
myeloid-derived suppressor cells, had a shorter PFS and could be used as complementary information together
with PET-2 to predict treatment response [22]. The blood-based markers are more practical as readily and serially
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obtainable and they can be used to plan the therapeutic strategy as well as to monitor tumor response throughout
treatment and patient follow-up.
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13 Alvaro T, Lejeune M, Salvadó MT et al. Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying
cytotoxic and regulatory T cells. Clin. Cancer Res. 11, 1467–1473 (2005).
14 Steidl C, Lee T, Shah SP et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N. Engl. J. Med. 62, 875–885
(2010).
15 Tan KL, Scott DW, Hong F et al. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative
study from the E2496 Intergroup trial. Blood 120, 3280–3287 (2012).
16 Guo B, Cen H, Tan X. Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin
lymphoma. BMC Med. 14, 159 (2016).
17 Traverse-Glehen A, Damotte D, Dartigues P et al. The combination of high expression of CD68-positive tumor-associated macrophages
and PET2-positivity predicts unfavorable outcome in patients with classical Hodgkin lymphoma treated in the Lysa AHL2011 study.
Blood 128, 1825 (2016).
18 Agostinelli C, Gallamini A, Stracqualursi L et al. The combined role of biomarkers and interim PET scan in prediction of treatment
outcome in classical Hodgkin’s lymphoma: a retrospective, European, multicentre cohort study. Lancet Haematol. 3 e467–e479 (2016).
19 Scott DW, Chan FC, Hong F et al. Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall
survival in advanced-stage classical Hodgkin lymphoma. J. Clin. Oncol. 31, 692–700 (2013).
20 Chan FC, Mottok A, Gerrie AS et al. A novel prognostic model based on tumor microenvironment biology in relapse biopsies predicts
post-autologous stem cell transplantation outcomes in classical Hodgkin lymphoma. Blood 128, 1093 (2016).
future science group www.futuremedicine.com 67
Commentary Agostinelli
21 Kanakry JA, Hong F, Martinez-Maza O et al. Serum biomarkers predict outcomes in advanced Hodgkin lymphoma independent of
international prognostic score (IPS) and treatment: correlative analysis from a Large North American Cooperative Group Trial. Blood
128, 2992 (2016).
22 Romano A, Parrinello NL, Vetro C et al. The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic
Hodgkin lymphoma. Oncotarget 7, 67333–67346 (2016).
68 Int. J. Hematol. Oncol. (2017) 6(3) future science group
